Therapy: A local approach to Raynaud phenomenon.
The current treatment options for Raynaud phenomenon are often ineffective and can have undesirable adverse effects. Topical, or transdermal, treatments that increase digital blood flow without systemic adverse effects are, therefore, an attractive option. A novel topical nitroglycerin formulation has shown promise in treating Raynaud attacks.
University of Manchester and Salford Royal Hospital, Salford, Manchester, UK. ariane.herrick@manchester.ac.uk
Ariane L
AL
Herrick
D000287:Administration, Topical; D004655:Emulsions; D005385:Fingers / Q000098:blood supply; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008833:Microcirculation / Q000187:drug effects; D005996:Nitroglycerin / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011928:Raynaud Disease / Q000188:drug therapy* / Q000503:physiopathology; D012039:Regional Blood Flow / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D004655:Emulsions; D014665:Vasodilator Agents; D005996:Nitroglycerin